Peptides · Neuro & cognitive (under FDA review)
ACTH-fragment peptide with physician-request review.
Why this needs to be personal
The evidence base for Semax is concentrated in Russian clinical and pharmacology literature, with use described for neurologic indications abroad. That record has not been converted into an FDA-approved US product or a modern US safety and dosing program.
Physicians may submit patient-specific prescription requests for Semax for pharmacy review. Certain preparations may be available now when clinically appropriate, lawfully prescribed, supported by patient-specific documentation, and approved by the dispensing pharmacy. Availability is determined case by case. This is not a consumer access promise; it is a clinical, sourcing, formulation, and regulatory review process. FDA has scheduled Semax-related bulk drug substances for discussion at the 23-24 Jul 2026 Pharmacy Compounding Advisory Committee meeting.
The legitimate US pathway is not to treat foreign approval or online availability as a substitute for pharmacy review. A patient-specific prescription request must be reviewed against US compounding requirements and the actual evidence record.
In brief
Semax is a small synthetic peptide developed in Russia in the late 1980s. It is a chemical analog of a fragment of adrenocorticotropic hormone (ACTH), specifically the part of ACTH numbered 4 through 10, with an extra three-amino-acid tail (Pro-Gly-Pro) that makes it resistant to rapid breakdown in the body. It is given as nasal drops.
In Russia, semax is approved as a prescription medicine for ischemic stroke, transient ischemic attack, cerebrovascular insufficiency, and (in children) attention and cognitive disorders 12. Most of the human clinical trials supporting these uses were conducted in the Russian Federation and published in Russian-language journals; Western regulators have not reviewed or approved semax.
Semax has no FDA approval in the United States. This ingredient is part of an evolving FDA review process. Physicians may submit patient-specific prescription requests for pharmacy review. Availability is determined case by case, and availability may change after FDA review, PCAC discussion, final agency action, or state-board guidance.
At a glance
Prescription review
Physicians may submit patient-specific prescription requests for Semax for pharmacy review. Certain preparations may be available now when clinically appropriate, lawfully prescribed, and approved by the dispensing pharmacy. Availability is determined case by case.
Real medicine, not gray market
A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.
A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.
What it is
Semax is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro (single-letter MEHFPGP). The first four residues correspond to positions 4 through 7 of adrenocorticotropic hormone (ACTH); the C-terminal Pro-Gly-Pro tripeptide is appended to confer resistance to aminopeptidase and carboxypeptidase degradation and to extend functional half-life relative to native ACTH(4-10), which is rapidly cleaved in plasma and tissue.
Semax was synthesized and characterized in the late 1980s by Ashmarin, Myasoedov, and colleagues at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, with the design hypothesis that ACTH(4-10) carries behaviorally active, melanocortin-related but glucocorticoid-independent CNS activity, and that proteolytic stabilization would yield a clinically tractable nootropic and neuroprotective agent 415. The pharmaceutical product is manufactured by Innovative Research Production Center 'Peptogen' (Moscow) and marketed in the Russian Federation and Eurasian Economic Union as Semax-MV 0.1% and 1% intranasal drops.
Outside the Russian Federation and EAEU, semax is not an approved medicinal product. In the United States it is not FDA-approved in any U.S. indication, is not a generally recognized as safe (GRAS) substance, and is not a listed dietary ingredient. FDA has placed semax under 503A bulk substance evaluation in Category 2, indicating identified safety concerns or insufficient evidence to support a positive determination; 503A patient-specific compounding from bulk semax is not permitted while the substance is in Category 2 2122.
How it works
Semax is a multimodal neuroactive peptide. Its principal CNS effects in preclinical studies are upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), together with their tyrosine kinase receptors trkB and trkA, in hippocampus, basal forebrain cholinergic nuclei, and ischemic cortical penumbra 658. Through this neurotrophin-axis activation, semax is hypothesized to support cholinergic neuron survival, synaptic plasticity, and post-ischemic functional recovery.
After focal cerebral ischemia-reperfusion in rat models, semax administration alters expression of large gene-expression panels related to inflammation, immune response, vascular remodeling, and apoptosis 41011. The pro-inflammatory mediator suppression and vascular-gene modulation profiles are mechanistically aligned with the clinical neuroprotection claim in acute ischemic stroke 14.
Semax exhibits mild mu-opioid receptor activity, contributing to its behavioral profile (anxiolytic-like and antinociceptive effects in rodent models) without producing classical opioid sedation, respiratory depression, or dependence at studied doses 1716. Peripheral binding to transthyretin has been proposed as an additional vector for neuroprotective signaling 20. Semax does not display glucocorticoid-axis effects characteristic of full-length ACTH (ACTH 1-39) because it lacks the melanocortin receptor-2 (MC2R) binding determinants required for adrenocortical steroidogenesis 71312.
Research history
The semax program originated in the late 1980s in the laboratory of N.F. Myasoedov and I.P. Ashmarin at the Institute of Molecular Genetics, Russian Academy of Sciences, Moscow. The design rationale was to stabilize a behaviorally active ACTH(4-7) sequence via a proteolytically resistant Pro-Gly-Pro extension. Russian preclinical work through the 1990s established a neuroprotective profile in focal cerebral ischemia models and a behavioral-stabilization profile in post-hypoxic developmental injury, leading to Russian Ministry of Health approval of Semax-MV intranasal drops for ischemic stroke and cerebrovascular insufficiency 1314.
The first Russian clinical report of semax in acute hemispheric ischemic stroke was published by Gusev and colleagues in 1997 (Zh Nevrol Psikhiatr) and described clinical and electrophysiological benefit during the acute period 1 11. A 2005 Russian-language report (Gusev et al.) described semax in prevention of disease progression and exacerbations in patients with cerebrovascular insufficiency 2 7. A 2018 Russian-language efficacy paper from the same group described semax across different stages of ischemic stroke 3 45. Russian preclinical mechanistic work in the 2000s established the BDNF/NGF axis as the principal pharmacological target, and Russian transcriptomic work from the 2010s and early 2020s extended the mechanistic picture to large-scale immune and inflammatory gene-expression modulation after focal ischemia 1068.
Western engagement with semax has been limited. The principal Western-journal hypothesis paper is Tsai (2007, Med Hypotheses), proposing semax for ADHD and Rett syndrome on mechanistic grounds 18. No FDA-registration phase 2 or phase 3 trial of semax has been reported in any indication. No Cochrane systematic review or large Western-led independent replication of the Russian stroke data exists. FDA has placed semax in Category 2 of its 503A bulk drug substance evaluation, indicating that the agency considers the available evidence insufficient or the safety profile insufficiently characterized to support 503A compounding 2122 12.
Timeline
Natural role
ACTH and its proteolytic fragments have been recognized since the 1970s as carrying behaviorally active, melanocortin-mediated CNS effects that are distinct from the steroidogenic action of full-length ACTH on the adrenal cortex. ACTH(4-10) was identified as a key behaviorally active fragment, but its therapeutic application was limited by rapid proteolytic degradation. The semax program represented an early-1990s peptide-engineering response: append a stabilizing tripeptide tail (Pro-Gly-Pro) to a behaviorally active ACTH fragment to yield a clinically tractable nootropic and neuroprotective agent.
Semax sits within a family of melanocortin-system-derived peptides studied for neuroprotection. The C-terminal Pro-Gly-Pro tripeptide is itself bioactive, activating neurotrophin transcription independently of the full heptapeptide 9, suggesting that semax acts in part through Pro-Gly-Pro-mediated mechanisms that may overlap with other glyprolines studied for cytoprotection.
Clinical contexts studied
Evidence should be interpreted in context for Semax. Any patient-specific request requires prescriber rationale and pharmacy review; availability is determined case by case.
Evidence should be interpreted in context for Semax. Any patient-specific request requires prescriber rationale and pharmacy review; availability is determined case by case.12391011121314
Evidence should be interpreted in context for Semax. Any patient-specific request requires prescriber rationale and pharmacy review; availability is determined case by case.
Evidence should be interpreted in context for Semax. Any patient-specific request requires prescriber rationale and pharmacy review; availability is determined case by case.1718
Experimental and preclinical only; not an approved indication anywhere.
Evidence should be interpreted in context for Semax. Any patient-specific request requires prescriber rationale and pharmacy review; availability is determined case by case.19
Compounded use
Physicians may submit patient-specific prescription requests for pharmacy review. For Semax, certain preparations may be available now when clinically appropriate, lawfully prescribed, and approved by the dispensing pharmacy. Availability is determined case by case and may depend on patient-specific documentation, ingredient status, source qualification, formulation feasibility, state requirements, and pharmacist judgment. The review starts with the evidence constraint: The evidence base for Semax is concentrated in Russian clinical and pharmacology literature, with use described for neurologic indications abroad. That record has not been converted into an FDA-approved US product or a modern US safety and dosing program.
This ingredient is part of an evolving FDA review process. RonanRx is monitoring FDA's PCAC process and any subsequent agency action. FDA has scheduled Semax-related bulk drug substances for discussion at the 23-24 Jul 2026 Pharmacy Compounding Advisory Committee meeting. Availability may change after FDA review, PCAC discussion, final agency action, or state-board guidance. For Semax, RonanRx ties that monitoring to the evidence limits described above and to any patient-specific documentation submitted by the prescriber.
Valid patient-specific prescription required. Supporting clinical rationale may be requested. Compounded medications are not FDA-approved. No consumer self-ordering, no office stock, no bulk dispensing. Requests for Semax are reviewed before any preparation is made or released. The legitimate US pathway is not to treat foreign approval or online availability as a substitute for pharmacy review. A patient-specific prescription request must be reviewed against US compounding requirements and the actual evidence record.
Formulations and routes
| Form | Concentration | Description |
|---|---|---|
| Intranasal drops (Russian Federation approved product) | 0.1% (1 mg/mL) and 1% (10 mg/mL) intranasal solution | Semax-MV is manufactured by Innovative Research Production Center 'Peptogen' (Moscow) and marketed in the Russian Federation and EAEU as a prescription intranasal drop preparation. The 0.1% strength is used for outpatient and pediatric indications; the 1% strength is used for acute neurological emergencies including ischemic stroke. The product is not FDA-approved and is not legally imported into the United States for prescription use.215 |
Routes used in published literature: intranasal.
Dosing
| Route | Population | Range | Duration | Study type |
|---|---|---|---|---|
| Intranasal | Adults with ischemic stroke (Russian Federation Semax-MV labeled regimen) | Russian-language label: 1% solution administered as intranasal drops totaling 12, 18 mg/day in divided doses during the acute period of ischemic stroke. Dosing ranges and durations vary across Russian clinical reports. | 10 days typical in published Russian trials | Russian Federation approved labeling and published Russian clinical reports123 |
| Intranasal | Adults with chronic cerebrovascular insufficiency (Russian Federation Semax-MV labeled regimen) | Russian-language label: 0.1% solution administered as intranasal drops totaling typically 600, 900 mcg/day in divided doses | 10, 14 day courses repeated per Russian clinical practice | Russian Federation approved labeling and published Russian clinical reports2 |
RonanRx does not publish a consumer dosing schedule for Semax. Any request requires a valid patient-specific prescription, supporting clinical rationale, and pharmacist review. Route, strength, dosing interval, monitoring expectations, and dispensing quantity would be determined case by case from the prescriber's documentation and pharmacy feasibility review.
Patients who travel abroad and have received semax in jurisdictions where it is approved should disclose this to U.S. prescribers, particularly in the context of stroke or cerebrovascular care, so that the prescriber can document the exposure history. Continuation of semax obtained outside the United States is not facilitated by RonanRx 123.
Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.
Safety
Published Russian clinical data describe a generally favorable tolerability profile for intranasal semax in adult stroke and cerebrovascular insufficiency populations, with adverse events typically limited to mild local nasal irritation and infrequent reports of headache or transient changes in blood pressure 123. The evidence base is small, concentrated in Russian-language journals, and not subject to the post-marketing pharmacovigilance infrastructure that supports U.S. or European regulatory decisions.
Long-term safety in pediatric populations, the population for which Semax-MV carries a Russian-Federation cognitive-deficit indication, is not well characterized by Western-standard controlled studies. Effects on hypothalamic-pituitary-adrenal axis development, neurotrophin-signaling-related off-target effects, and long-term cognitive trajectories have not been studied at a level that would support FDA approval. FDA's placement of semax in Category 2 of the 503A bulk drug substance evaluation reflects this evidentiary gap and the agency's safety-concern threshold 2122.
Patients who obtain semax from non-pharmaceutical sources (research-chemical suppliers, internet vendors) face additional safety risks unrelated to the molecule itself: unverified identity, potency, sterility, and endotoxin content. Such material is not subject to USP <797> sterile-compounding controls and may carry contamination, mis-dosing, and counterfeit risks. Physicians may submit patient-specific prescription requests for pharmacy review. Availability is determined case by case.
Russian Federation labeling for Semax-MV lists contraindications including pregnancy, lactation, acute psychotic states, severe endocrine disorders, history of convulsive seizures, and known hypersensitivity to the peptide. These contraindications derive from the Russian regulatory record and have not been independently evaluated by FDA or EMA.
Because semax is not FDA-approved, is not available through legitimate U.S. pharmaceutical channels, and is in FDA Category 2 for 503A compounding evaluation, the practical U.S. contraindication is that semax should not be used outside an authorized investigational protocol 2122.
Honest gap. No formal human drug-drug interaction studies of semax have been published. Russian-Federation labeling does not enumerate specific drug-drug interactions. Semax is a small peptide cleared by proteolytic catabolism and is not expected to participate in cytochrome P450-mediated metabolic interactions; however, this expectation is mechanistic rather than empirically demonstrated in dedicated DDI studies.
Russian-language clinical reports describe mild local nasal irritation, occasional transient headache, and infrequent transient blood pressure changes as the principal observed adverse events with intranasal semax at labeled doses 123. Serious adverse events have not been reported at clinically significant frequency in the published Russian trial literature, but these reports lack the systematic adverse-event capture, central adjudication, and pharmacovigilance follow-through expected of FDA-registration trials.
Off-label and research-chemical-channel use carries safety considerations unrelated to the molecule itself: contamination, identity errors, dose miscalculation, and counterfeit product. These risks are not captured in the published clinical literature because they are characteristic of the unregulated supply chain rather than of the peptide. RonanRx is not a source of semax under any compounding pathway.
Monitoring
No RonanRx-specific monitoring protocol has been established for Semax. If a patient-specific prescription is submitted, supporting clinical rationale may be requested, and monitoring expectations would be reviewed case by case against the published evidence, route, sterile or nonsterile status, concomitant therapies, and patient risk factors.
Special populations
No FDA-recognized use guidance for Semax in this population is established. Any patient-specific request would require prescriber rationale, patient-specific risk review, and pharmacist approval before dispensing.
No FDA-recognized use guidance for Semax in this population is established. Any patient-specific request would require prescriber rationale, patient-specific risk review, and pharmacist approval before dispensing.
No FDA-recognized use guidance for Semax in this population is established. Any patient-specific request would require prescriber rationale, patient-specific risk review, and pharmacist approval before dispensing.
No FDA-recognized use guidance for Semax in this population is established. Any patient-specific request would require prescriber rationale, patient-specific risk review, and pharmacist approval before dispensing.
No FDA-recognized use guidance for Semax in this population is established. Any patient-specific request would require prescriber rationale, patient-specific risk review, and pharmacist approval before dispensing.
No FDA-recognized use guidance for Semax in this population is established. Any patient-specific request would require prescriber rationale, patient-specific risk review, and pharmacist approval before dispensing.
Evidence quality
Evidence for semax is concentrated in Russian-language journals and in Russian preclinical mechanistic work 465. The clinical evidence base for the principal Russian indications (acute ischemic stroke, cerebrovascular insufficiency, pediatric cognitive deficit) consists of small to moderate single-country trials reported across approximately three decades 123; these reports have not been replicated in Western controlled trials, have not been systematically reviewed at a level supporting FDA approval, and do not meet the evidentiary standard required for FDA marketing authorization or for a positive determination on the 503A bulk drug substance list.
Preclinical mechanistic evidence is substantially stronger than the clinical evidence base 789. Semax has a reproducible BDNF/NGF-axis activation profile, a reproducible post-ischemic gene-expression-modulation profile in rat focal-ischemia models, a characterized intranasal-PK substrate 15, and a documented developmental-injury behavioral phenotype 17 13. The preclinical-clinical translation gap, coherent mechanism plus modest, geographically concentrated clinical evidence, is the principal reason for the FDA Category 2 placement in the 503A bulk substance evaluation 2122 14. RonanRx documents this evidence base so physician-submitted requests can be reviewed against the literature, the FDA process, and patient-specific rationale 101112.
Major studies
| Study | Design | Participants | Duration | Finding |
|---|---|---|---|---|
| Gusev et al. (1997, Zh Nevrol Psikhiatr Im S S Korsakova), first clinical report of semax in acute ischemic stroke | Russian-language clinical and electrophysiological study of semax in acute hemispheric ischemic stroke | — | — | Reported clinical and electrophysiological benefit of intranasal semax during the acute period of hemispheric ischemic stroke; founding clinical citation for the Russian-Federation stroke indication 1 |
| Gusev et al. (2005, Zh Nevrol Psikhiatr), semax in cerebrovascular insufficiency | Russian-language clinical report of semax in prevention of disease progression and exacerbations in patients with cerebrovascular insufficiency | — | — | Reported reduction in disease progression and exacerbation frequency on intranasal semax in adults with chronic cerebrovascular insufficiency 2 |
| Gusev et al. (2018, Zh Nevrol Psikhiatr), semax across stages of ischemic stroke | Russian-language efficacy report across acute, subacute, and recovery stages of ischemic stroke | — | — | Reported efficacy of semax in the treatment of patients at different stages of ischemic stroke; reaffirmed the Russian-Federation acute-stroke indication 3 |
| Dolotov et al. (2006, J Neurochem), basal forebrain BDNF | Preclinical pharmacology study in rats using radiolabeled semax binding and BDNF protein quantitation | — | — | Semax binds specifically to sites in rat basal forebrain and increases BDNF protein levels in basal forebrain cholinergic nuclei 5 |
| Dolotov et al. (2006, Brain Res), hippocampal BDNF/trkB | Preclinical pharmacology study in rats characterizing semax effects on BDNF and trkB gene expression | — | — | Semax regulates BDNF and trkB receptor expression in the rat hippocampus, consistent with a hippocampal-cognitive substrate for the nootropic claim 6 |
| Dmitrieva et al. (2010, Cell Mol Neurobiol), Pro-Gly-Pro bioactivity | Preclinical post-ischemia transcription study in rats comparing semax with its C-terminal Pro-Gly-Pro fragment | — | — | Both semax and its C-terminal Pro-Gly-Pro fragment activate transcription of neurotrophins and their receptor genes after cerebral ischemia, indicating that the Pro-Gly-Pro extension is itself bioactive 9 |
| Medvedeva et al. (2014, BMC Genomics), focal-ischemia transcriptome | Genome-wide transcriptional analysis of rat brain in a focal cerebral ischemia model with and without semax | — | — | Semax preferentially affects genes related to immune and vascular systems in rat brain focal ischemia, providing a transcriptome-level substrate for the Russian neuroprotection claim 10 |
| Filippenkov et al. (2024, Biomedicines), 24-hour transcriptome compensation | Preclinical transcriptomic study of ACTH-like peptides including semax 24 hours after experimental stroke in rats | — | — | Semax-class peptides compensate the rat brain gene-expression profile disrupted by ischemia a day after experimental stroke, supporting the post-acute neuroprotection model 14 |
| Shevchenko et al. (2006, Bioorg Khim), intranasal pharmacokinetics | Tritium-labeled semax PK study characterizing penetration into rat brain and blood after intranasal administration | — | — | Established the principal published PK substrate for intranasal semax dosing; demonstrated measurable brain exposure after intranasal administration 15 |
| Maslova et al. (2003, Neurosci Behav Physiol), post-hypoxia ADHD-like model | Preclinical developmental rat model of ante- and postnatal hypoxia with hyperactivity and learning deficits | — | — | Semax corrects post-hypoxic hyperactivity and learning deficits, providing the preclinical rationale cited in the Russian-Federation pediatric ADHD/cognitive indication 17 |
| Tsai (2007, Med Hypotheses), ADHD and Rett syndrome hypothesis | Mechanism-driven hypothesis paper | — | — | Proposed semax as a candidate ADHD and Rett syndrome therapeutic on the basis of its BDNF-axis and cholinergic effects; not a controlled clinical trial 18 |
Mechanism detail
Neurotrophin axis. Dolotov and colleagues (2003, Dokl Biol Sci) reported that intranasal semax stimulates BDNF expression across multiple rat brain areas in vivo 4. Follow-on work in J Neurochem (2006) demonstrated specific semax binding sites in rat basal forebrain and a corresponding increase in BDNF protein in basal forebrain cholinergic nuclei 5; a parallel Brain Research report demonstrated regulation of BDNF and trkB receptor expression in the hippocampus 6. Agapova et al. (2007, Neurosci Lett) and Shadrina et al. (2010, J Mol Neurosci) extended the analysis to NGF gene expression and characterized the temporal dynamics of NGF and BDNF transcript induction after semax administration 78. Dmitrieva et al. (2010, Cell Mol Neurobiol) showed that both semax and its C-terminal Pro-Gly-Pro fragment activate transcription of neurotrophins and their receptor genes in the rat brain after cerebral ischemia, indicating that the Pro-Gly-Pro extension is itself bioactive 9.
Post-ischemic transcriptomics. Medvedeva and colleagues (2014, BMC Genomics) reported genome-wide expression profiling in the rat focal-ischemia model and demonstrated that semax preferentially affects genes related to the immune and vascular systems 10. A 2017 follow-up in Mol Genet Genomics narrowed the focus to immune-response gene regulation after ischemic brain injury 11. Dergunova et al. (2021) demonstrated that semax suppresses mRNA transcripts encoding pro-inflammatory mediators induced by reversible cerebral ischemia 12. Filippenkov et al. (2020 and 2024) reported broad transcriptome compensation by ACTH-like peptides after ischemia-reperfusion, with the 2024 Biomedicines paper documenting that semax-class peptides restore ischemia-disrupted gene expression profiles by 24 hours post-stroke 1314.
Opioidergic and behavioral pharmacology. Maslova et al. (2003, Neurosci Behav Physiol) reported that semax corrects post-hypoxic hyperactivity and learning deficits in a developmental rat model, consistent with a behavioral-stabilization profile relevant to ADHD-like phenotypes 17. Grivennikov et al. (2008, Restor Neurol Neurosci) characterized semax effects on rat basal forebrain cholinergic neurons and reported behavioral activity without the dependence liability associated with full opioid agonists 16. Tsai (2007, Med Hypotheses) proposed semax as a candidate ADHD and Rett syndrome therapeutic on mechanistic grounds 18.
Pharmacokinetics. Shevchenko et al. (2006, Bioorg Khim) characterized the kinetics of semax penetration into rat brain and blood after intranasal administration using tritium-labeled peptide, providing the principal published PK substrate for the clinical intranasal-drop dosing regimen 15. The Pro-Gly-Pro C-terminal extension is critical: native ACTH(4-10) is degraded within minutes in plasma, whereas semax retains measurable CNS bioactivity over hours after intranasal dosing.
Pharmacology
Semax is administered intranasally in the Russian-Federation approved product. Shevchenko et al. (2006) characterized intranasal-route kinetics in rats using tritium-labeled peptide, demonstrating measurable CNS exposure after intranasal administration 15. The C-terminal Pro-Gly-Pro tripeptide is a critical PK feature: it confers proteolytic stability relative to native ACTH(4-10), which is degraded within minutes in plasma. Detailed human PK parameters (Cmax, AUC, t1/2, brain-to-plasma ratio) have not been published in English-language peer-reviewed sources at the level required for FDA labeling.
Semax is cleared by proteolytic catabolism. CYP-mediated metabolism is not expected to be a relevant pathway. No formal renal- or hepatic-impairment PK studies have been published. The Pro-Gly-Pro fragment is itself bioactive and may contribute to post-administration pharmacology after the parent peptide is cleaved 9.
Principal pharmacodynamic effects characterized in preclinical and translational work are upregulation of BDNF and NGF and their receptors in hippocampus and basal forebrain, modulation of immune and vascular gene expression in post-ischemic brain, mild mu-opioid receptor activity, and possible transthyretin binding 465111316. Clinical PD endpoints used in the Russian literature include neurological severity scales (NIHSS-equivalent), electrophysiological measures, and cognitive testing batteries; these endpoints have not been bridged to FDA-recognized endpoint instruments through dedicated comparative studies 7810121420.
Storage
If a Semax preparation is approved after pharmacy review, RonanRx applies source documentation, formulation records, lot traceability, release checks, and storage controls appropriate to the actual dosage form. Research-use vial storage practices do not substitute for pharmacy-assigned storage, beyond-use dating, sterility controls when applicable, or recallable batch records.
RonanRx operations
Physicians may submit patient-specific prescription requests for pharmacy review. For Semax, certain preparations may be available now when clinically appropriate, lawfully prescribed, and approved by the dispensing pharmacy. Availability is determined case by case and may depend on patient-specific documentation, ingredient status, source qualification, formulation feasibility, state requirements, and pharmacist judgment. The review starts with the evidence constraint: The evidence base for Semax is concentrated in Russian clinical and pharmacology literature, with use described for neurologic indications abroad. That record has not been converted into an FDA-approved US product or a modern US safety and dosing program.
This ingredient is part of an evolving FDA review process. RonanRx is monitoring FDA's PCAC process and any subsequent agency action. FDA has scheduled Semax-related bulk drug substances for discussion at the 23-24 Jul 2026 Pharmacy Compounding Advisory Committee meeting. Availability may change after FDA review, PCAC discussion, final agency action, or state-board guidance. For Semax, RonanRx ties that monitoring to the evidence limits described above and to any patient-specific documentation submitted by the prescriber.
Valid patient-specific prescription required. Supporting clinical rationale may be requested. Compounded medications are not FDA-approved. No consumer self-ordering, no office stock, no bulk dispensing. Requests for Semax are reviewed before any preparation is made or released. The legitimate US pathway is not to treat foreign approval or online availability as a substitute for pharmacy review. A patient-specific prescription request must be reviewed against US compounding requirements and the actual evidence record.
For Semax, the pharmacist review starts before any preparation is made. Valid patient-specific prescription required. Supporting clinical rationale may be requested. The pharmacist reviews ingredient status, sourcing, formulation feasibility, state requirements, patient-specific documentation, and whether dispensing is appropriate case by case.
If a Semax preparation is approved after pharmacy review, RonanRx applies source documentation, formulation records, lot traceability, release checks, and storage controls appropriate to the actual dosage form. Research-use vial storage practices do not substitute for pharmacy-assigned storage, beyond-use dating, sterility controls when applicable, or recallable batch records.
FAQ
Physicians may submit patient-specific prescription requests for pharmacy review. Certain preparations may be available now when clinically appropriate, lawfully prescribed, and approved by the dispensing pharmacy. Availability is determined case by case. Compounded medications are not FDA-approved, and no consumer self-ordering, office stock, or bulk dispensing is offered.2122
Russian Federation approval of Semax-MV intranasal drops is based on a body of Russian-language clinical trials and a Russian Ministry of Health regulatory process. FDA approval requires evidence that meets U.S. statutory and regulatory standards, including controlled trials reviewed under the FDA framework 23. No FDA-registration trial of semax has been reported, and FDA's current placement of semax in Category 2 under 503A bulk substance evaluation reflects the agency's assessment that the available safety or efficacy evidence is insufficient at this time 21221.
FDA's 503A bulk drug substance evaluation places candidate substances into categories. Category 1 substances are acceptable for 503A compounding while FDA finalizes formal listing. Category 2 substances are not acceptable for 503A compounding because FDA has identified significant safety risk or insufficient evidence at the bulk-substance level 2122. Semax is currently in Category 2.
The clinical evidence base is concentrated in Russian-language journals and consists of small to moderate single-country trials in acute ischemic stroke and chronic cerebrovascular insufficiency reported between 1997 and 2018 123. The preclinical mechanistic literature is substantially larger and characterizes BDNF/NGF-axis activation, post-ischemic transcriptome modulation, mild mu-opioid receptor activity, and intranasal pharmacokinetics 4. Western-journal coverage is limited; the principal English-language hypothesis paper is Tsai (2007, Medical Hypotheses) on ADHD and Rett syndrome 518.
RonanRx cannot speak for other pharmacies, but under federal law no 503A compounding pharmacy can lawfully compound from a bulk substance in FDA Category 2 of the 503A bulk drug substance evaluation 2122. Pharmacies that compound and dispense semax from bulk are doing so contrary to the FDA framework. Patients should be cautious about any source that markets compounded semax in the United States.
Semax is not specifically named on the World Anti-Doping Agency Prohibited List as of the current revision 23. Athletes should note, however, that peptides marketed for cognitive enhancement or recovery may fall under WADA category S0 (non-approved substances), substances not currently approved by any governmental regulatory health authority for human therapeutic use, which is prohibited at all times. Athletes considering semax for any reason should consult a sports physician and the WADA framework before use.
Physicians may submit patient-specific prescription requests for pharmacy review. Certain preparations may be available now when clinically appropriate, lawfully prescribed, and approved by the dispensing pharmacy. Availability is determined case by case. Compounded medications are not FDA-approved, and no consumer self-ordering, office stock, or bulk dispensing is offered.2122
Clinician resource
The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.
References
How to access
Physicians may submit patient-specific prescription requests for Semax for pharmacy review. Availability is determined case by case, and RonanRx is monitoring FDA's PCAC process and any subsequent agency action.
For doctors
A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.
Patient with a doctor
If your doctor has already prescribed Semax, sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.
Patient without a doctor
RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for Semax.
Related